Text size A - A+

Investor Relations

valeant_logoValeant Pharmaceuticals International, Inc., (NYSE: VRX) (TSX: VRX) completed its acquisition of Bausch + Lomb on August 5, 2013. Bausch + Lomb will retain its name and become a division of Valeant. Valeant's existing ophthalmology businesses will be integrated into the Bausch + Lomb division, creating a global eye health platform with estimated pro forma 2013 net revenue of more than $3.5 billion. For Investor Relations information on Valeant, click here.